Beraprost and Overall Survival in Cats with Chronic Kidney Disease.

beraprost chronic kidney disease feline overall survival progression-free survival

Journal

Veterinary sciences
ISSN: 2306-7381
Titre abrégé: Vet Sci
Pays: Switzerland
ID NLM: 101680127

Informations de publication

Date de publication:
13 Jul 2023
Historique:
received: 11 05 2023
revised: 07 07 2023
accepted: 11 07 2023
medline: 28 7 2023
pubmed: 28 7 2023
entrez: 28 7 2023
Statut: epublish

Résumé

Overall survival is the most important outcome for treatment response in feline chronic kidney disease (CKD). Beraprost has been shown to reduce the kidney function decline in cats with International Renal Interest Society (IRIS) stage 2 and 3 CKD. However, the association with prolonged survival has not yet been examined. To assess the relationship between beraprost and overall survival in cats with CKD in real clinical practice. Client-owned cats with IRIS stage 3 CKD ( A retrospective cohort study based on data from electronic medical records of one hospital. The cohort was divided into "beraprost therapy" and "no beraprost therapy" groups, and survival analyses revealed that overall survival was significantly longer in the beraprost therapy group, using Kaplan-Meier curves ( In feline patients with CKD, beraprost therapy is associated with better overall survival.

Sections du résumé

BACKGROUND BACKGROUND
Overall survival is the most important outcome for treatment response in feline chronic kidney disease (CKD). Beraprost has been shown to reduce the kidney function decline in cats with International Renal Interest Society (IRIS) stage 2 and 3 CKD. However, the association with prolonged survival has not yet been examined.
OBJECTIVE OBJECTIVE
To assess the relationship between beraprost and overall survival in cats with CKD in real clinical practice.
ANIMALS METHODS
Client-owned cats with IRIS stage 3 CKD (
METHODS METHODS
A retrospective cohort study based on data from electronic medical records of one hospital.
RESULTS RESULTS
The cohort was divided into "beraprost therapy" and "no beraprost therapy" groups, and survival analyses revealed that overall survival was significantly longer in the beraprost therapy group, using Kaplan-Meier curves (
CONCLUSIONS CONCLUSIONS
In feline patients with CKD, beraprost therapy is associated with better overall survival.

Identifiants

pubmed: 37505864
pii: vetsci10070459
doi: 10.3390/vetsci10070459
pmc: PMC10384921
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Vet Intern Med. 2018 Jan;32(1):236-248
pubmed: 29131397
J Am Vet Med Assoc. 2009 Jun 1;234(11):1398-403
pubmed: 19480619
Circ Res. 2003 Sep 19;93(6):523-30
pubmed: 12919953
Nat Rev Nephrol. 2013 Feb;9(2):99-111
pubmed: 23247571
J Vet Intern Med. 2006 Sep-Oct;20(5):1054-64
pubmed: 17063696
J Vet Intern Med. 2016 Sep;30(5):1661-1666
pubmed: 27527534
Prostaglandins Other Lipid Mediat. 2014 Aug;112:16-26
pubmed: 24992870
J Vet Intern Med. 2006 Sep-Oct;20(5):1074-9
pubmed: 17063698
J Vet Intern Med. 2019 Sep;33(5):1921-1925
pubmed: 31305000
J Vet Cardiol. 2015 Dec;17 Suppl 1:S244-57
pubmed: 26776583
Eur J Pharmacol. 2013 Aug 15;714(1-3):325-31
pubmed: 23911885
J Vet Intern Med. 2007 Sep-Oct;21(5):906-16
pubmed: 17939542
Ann Intern Med. 1983 Oct;99(4):544-50
pubmed: 6625387
BMJ. 1996 May 11;312(7040):1215-8
pubmed: 8634569
Vet J. 2019 Feb;244:1-6
pubmed: 30825884
Vet Comp Oncol. 2016 Dec;14(4):e126-e134
pubmed: 25303015
J Vet Intern Med. 2007 May-Jun;21(3):402-9
pubmed: 17552443
J Am Soc Nephrol. 2002 Mar;13(3):806-816
pubmed: 11856789
J Vet Intern Med. 2015 Nov-Dec;29(6):1494-501
pubmed: 26403212
J Vet Intern Med. 2015 Nov-Dec;29(6):1479-87
pubmed: 26474314
J Vet Med Sci. 2007 Oct;69(10):1015-23
pubmed: 17984588
J Am Soc Nephrol. 2004 Aug;15(8):1983-92
pubmed: 15284284
J Feline Med Surg. 2009 Mar;11(3):211-8
pubmed: 19237136
J Vet Intern Med. 2008 Mar-Apr;22(2):317-24
pubmed: 18371026
J Endocrinol. 2002 Oct;175(1):217-23
pubmed: 12379506
J Feline Med Surg. 2016 Mar;18(3):219-39
pubmed: 26936494
J Vet Intern Med. 2011 Sep-Oct;25(5):1057-65
pubmed: 21985139
Pharmacology. 1992;45(2):61-70
pubmed: 1523215
J Small Anim Pract. 2015 Sep;56(9):537-52
pubmed: 26331869
J Small Anim Pract. 1998 Feb;39(2):78-85
pubmed: 9513888
J Vet Cardiol. 2008 Dec;10(2):117-23
pubmed: 19027388
J Vet Intern Med. 2006 May-Jun;20(3):528-35
pubmed: 16734085
J Vet Intern Med. 2010 Jul-Aug;24(4):863-9
pubmed: 20649748
J Vet Intern Med. 2012 Mar-Apr;26(2):275-81
pubmed: 22269057
J Vet Intern Med. 2008 Sep-Oct;22(5):1111-7
pubmed: 18691369

Auteurs

Hiroyuki Ito (H)

Ichikawa General Hospital, Kariya Animal Hospital Group, Chiba 272-0034, Japan.

Takumi Matsuura (T)

Toray Industries, Inc., Tokyo 103-8666, Japan.

Tadashi Sano (T)

School of Veterinary Medicine, Rakuno Gakuen University, Hokkaido 069-8501, Japan.

Classifications MeSH